Business Context and Reporting Period
This Form 8-K reports on events occurring on June 18, 2025, regarding Dogwood Therapeutics, Inc. (DWTX), a Delaware corporation listed on the Nasdaq Capital Market. The filing details the outcomes of the Company's Annual Meeting of Stockholders, including the election of directors, ratification of auditors, and approval of an equity plan amendment.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and equity plan adjustments rather than financial performance metrics.
Material Changes and Corporate Actions
- Equity Plan Amendment: Stockholders approved Amendment No. 2 to the Amended and Restated Equity Incentive Plan. This increases the number of shares reserved for issuance by 108,612 shares, raising the total from 82,500 to 191,112 shares. The plan reflects automatic adjustments following a 25-for-1 reverse stock split effective October 9, 2024.
- Director Elections: Seven nominees were elected to the Board of Directors: Abel De La Rosa, Ph.D.; Greg Duncan; David Keefer; John C. Thomas, Jr.; Melvin Toh, M.B.B.S.; Richard J. Whitley, M.D.; and Alan Yu.
- Auditor Ratification: The appointment of Forvis Mazars, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified.
Voting Results and Management Commentary
At the Annual Meeting, holders of 921,595 shares (48.22% of voting power) were present, constituting a quorum. All matters were approved with the required votes.
| Matter | For | Against | Abstain/Withheld | Broker Non-Vote |
|---|---|---|---|---|
| Election of Directors (Aggregate) | ~1,961,636 | N/A | ~15,336 | 4,471,663 |
| Ratification of Auditor | 888,808 | 31,671 | 1,116 | 0 |
| Equity Plan Amendment | 275,020 | 6,482 | 1,284 | 638,809 |
Note: Broker non-votes were significant for the director elections and equity plan amendment but did not affect the outcome as these matters required a plurality or majority of votes cast.
Investor Verification Checklist
- Verify the impact of the increased share reserve (191,112 shares) on potential future dilution.
- Confirm the terms of the 25-for-1 reverse stock split referenced in the equity plan adjustment.
- Review the full text of the Amended and Restated 2020 Equity Incentive Plan (Exhibit 10.1) for specific vesting and exercise terms.
- Monitor upcoming financial filings (10-Q/10-K) for the first reported financial metrics, as none are included in this 8-K.